Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis
Abstract As commonly used lipid-lowering drugs, the efficacy and safety of statins, ezetimibe, and fibrates, either alone or in combination, have rarely been systematically evaluated. Therefore, we conducted a network meta-analysis to assess their efficacy and safety in patients with hyperlipidemia....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | European Journal of Medical Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40001-025-02805-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433021231398912 |
|---|---|
| author | Shujie Zhang Tingting Sun Lina Song Xiaodong Jin Bo Li |
| author_facet | Shujie Zhang Tingting Sun Lina Song Xiaodong Jin Bo Li |
| author_sort | Shujie Zhang |
| collection | DOAJ |
| description | Abstract As commonly used lipid-lowering drugs, the efficacy and safety of statins, ezetimibe, and fibrates, either alone or in combination, have rarely been systematically evaluated. Therefore, we conducted a network meta-analysis to assess their efficacy and safety in patients with hyperlipidemia. In this study, we searched PubMed, the Cochrane Library, and Web of Science within our system. We included randomized controlled trials (RCTs) that compared the monotherapy or combination therapy of statins, ezetimibe, and fibrates for hyperlipidemia. Data analysis was performed using Stata 17.0 software. Each result is presented as the mean difference (MD) or odds ratio (OR) along with the 95% confidence interval (CI) and the surface under the cumulative ranking curve (SUCRA). A total of 30 studies, involving 10,219 patients, were included to analyze 12 different interventions. Combination therapy demonstrated superior therapeutic effects compared to monotherapy. Moderate-intensity statin + ezetimibe showed good efficacy and acceptable safety in reducing LDL cholesterol, while moderate-intensity statin + fibrate was a better choice for treating mixed dyslipidemia. |
| format | Article |
| id | doaj-art-79f635a25fd04e40a718a48c75c8d85b |
| institution | Kabale University |
| issn | 2047-783X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | European Journal of Medical Research |
| spelling | doaj-art-79f635a25fd04e40a718a48c75c8d85b2025-08-20T03:27:11ZengBMCEuropean Journal of Medical Research2047-783X2025-06-0130111910.1186/s40001-025-02805-yEfficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysisShujie Zhang0Tingting Sun1Lina Song2Xiaodong Jin3Bo Li4School of Clinical Medicine, Shandong Second Medical UniversitySchool of Clinical Medicine, Shandong Second Medical UniversityDepartment of Health Education, Maternal and Child, Health Care Hospital of ZiboDepartment of Geriatrics, Zibo Central HospitalDepartment of Cardiology, Zibo Central HospitalAbstract As commonly used lipid-lowering drugs, the efficacy and safety of statins, ezetimibe, and fibrates, either alone or in combination, have rarely been systematically evaluated. Therefore, we conducted a network meta-analysis to assess their efficacy and safety in patients with hyperlipidemia. In this study, we searched PubMed, the Cochrane Library, and Web of Science within our system. We included randomized controlled trials (RCTs) that compared the monotherapy or combination therapy of statins, ezetimibe, and fibrates for hyperlipidemia. Data analysis was performed using Stata 17.0 software. Each result is presented as the mean difference (MD) or odds ratio (OR) along with the 95% confidence interval (CI) and the surface under the cumulative ranking curve (SUCRA). A total of 30 studies, involving 10,219 patients, were included to analyze 12 different interventions. Combination therapy demonstrated superior therapeutic effects compared to monotherapy. Moderate-intensity statin + ezetimibe showed good efficacy and acceptable safety in reducing LDL cholesterol, while moderate-intensity statin + fibrate was a better choice for treating mixed dyslipidemia.https://doi.org/10.1186/s40001-025-02805-yNetwork analysisCholesterolLipidsAdverse eventsAdverse drug reactionsEfficacy |
| spellingShingle | Shujie Zhang Tingting Sun Lina Song Xiaodong Jin Bo Li Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis European Journal of Medical Research Network analysis Cholesterol Lipids Adverse events Adverse drug reactions Efficacy |
| title | Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis |
| title_full | Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis |
| title_fullStr | Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis |
| title_full_unstemmed | Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis |
| title_short | Efficacy and safety of statins, ezetimibe, and fibrates monotherapy or combination therapy for hyperlipidemia: a systematic review and network meta-analysis |
| title_sort | efficacy and safety of statins ezetimibe and fibrates monotherapy or combination therapy for hyperlipidemia a systematic review and network meta analysis |
| topic | Network analysis Cholesterol Lipids Adverse events Adverse drug reactions Efficacy |
| url | https://doi.org/10.1186/s40001-025-02805-y |
| work_keys_str_mv | AT shujiezhang efficacyandsafetyofstatinsezetimibeandfibratesmonotherapyorcombinationtherapyforhyperlipidemiaasystematicreviewandnetworkmetaanalysis AT tingtingsun efficacyandsafetyofstatinsezetimibeandfibratesmonotherapyorcombinationtherapyforhyperlipidemiaasystematicreviewandnetworkmetaanalysis AT linasong efficacyandsafetyofstatinsezetimibeandfibratesmonotherapyorcombinationtherapyforhyperlipidemiaasystematicreviewandnetworkmetaanalysis AT xiaodongjin efficacyandsafetyofstatinsezetimibeandfibratesmonotherapyorcombinationtherapyforhyperlipidemiaasystematicreviewandnetworkmetaanalysis AT boli efficacyandsafetyofstatinsezetimibeandfibratesmonotherapyorcombinationtherapyforhyperlipidemiaasystematicreviewandnetworkmetaanalysis |